“narrowly non-significant”

Although the correlation was significant in the AD/WT groups combined, only a narrowly non-significant tendency (R=0.913, P = 0.058) was observed in the AD group isolated.

In addition, when looking at the number of 5-FU dose reductions at the patient level, study participants with newly diagnosed het_HapB3 status had a higher, but narrowly non-significant risk of 5-FU dose reductions ( p = 0.06, Table A.16) below the cut-off of 75% of the planned 5-FU dose compared to DPYD -WT carriers.

In contrast to these findings, one study reported that the difference in quality of life index (QLI) score between gMG patients and healthy controls was narrowly non-significant [ 23 ].

However, it should be noted that the difference between individuals with experience and those without experience was only narrowly non-significant.